Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The firm's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Industry: Pharmaceutical Preparations Peers: ABVC Biopharma Inc AIM ImmunoTech Inc Ainos Inc Neurogene Inc Oruka Therapeutics Inc Avalo Therapeutics Inc Codiak BioSciences, Inc. Marker Therapeutics Inc Maia Biotechnology Inc